Screen LibraryTargeting cell survival pathways to enhance response to chemotherapy /
"Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have be...
Saved in:
| Group Author: | |
|---|---|
| Published: |
Elsevier/Academic Press,
|
| Publisher Address: | London, United Kingdom : |
| Publication Dates: | [2018] |
| Literature type: | Book |
| Language: | English |
| Series: |
Cancer sensitizing agents for chemotherapy,
volume 3 |
| Subjects: | |
| Summary: |
"Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have been described, and continue to be described, which contribute to cell survival in the face of chemotherapy treatment. Key pathways leading to chemoresistance emanate from growth factor receptors, PI3K, STAT3, anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage response pathway. New advances have underscored the potential of targeting each of these cell survival mechanisms to improve responsiveness to chemotherapy. This book reviews these recent advances and provides a foundational background and hints of new opportunities for basic, translational, and clinical investigators focused on improving therapeutic responses to chemotherapy. Presents cutting-edge agents and approaches with proved success in different model systems that can be translated to a different type of cancer. Brings updated information to be used to propose new clinical trials investigating innovative strategies for improving responses to chemotherapy. Provides mechanistic details to help guide the design of laboratory studies associated with clinical trials"-- |
| Carrier Form: | xvi, 292 pages : color illustrations ; 25 cm. |
| Bibliography: | Includes bibliographical references and index. |
| ISBN: |
9780128164327 0128164328 |
| Index Number: | RC271 |
| CLC: | R730.53 |
| Call Number: | R730.53/T185-4 |
| Contents: |
Targeting members of the epidermal growth factor receptor family to improve response to chemotherapy / Targeting the hepatocyte growth factor receptor to overcome resistance to targeted therapies / Roles for AXL and MERTK in resistance to cytotoxic and targeted therapies / The JNK pathway in drug resistance / Fibroblast growth factor receptor inhibitors: enhancing therapeutic strategies for solid tumors / PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs / STAT3 as a major contributor to chemoresistance / Targeting the Hippo pathway to improve response to chemotherapy / Modulation of the epigenome (methylome) to improve chemotherapeutic efficacy / Targeting the ataxia telangiectasia and Rad3 signaling pathway to overcome chemoresistance in cancer / PARP inhibition to enhance response to chemotherapy / Autophagy inhibition and chemosensitization in cancer therapy / Targeting necroptosis in antitumor therapy / |